- Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) announced results from a Phase 2 study of cemdisiran for immunoglobulin A nephropathy (IgAN).
- Cemdisiran is an investigational RNAi therapeutic targeting the C5 component of the complement pathway and is under development in collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
- New results demonstrated a 36% reduction in 24-hour urine total protein and a higher proportion, 32% versus 13%, of patients treated with cemdisiran as compared to those on placebo, respectively, achieving greater than or equal to 50% reduction in 24-hour UPCR.
- Related: Why Alnylam Pharma Shares Are Trading Higher During Premarket Session.
- Spot urine data were consistent with 24-hour urine data, with the initial onset of treatment effect emerging as early as Week 8 and remaining stable over time. Patients on cemdisiran achieved a 46% placebo-adjusted reduction from baseline in spot UPCR at 32 weeks.
- The results showed that cemdisiran was generally well tolerated with no adverse events. One death occurred in the cemdisiran arm due to cardiorespiratory collapse; this was not considered related to the study drug.
- Price Action: ALNY shares are down 0.68% at $209.51 on the last check Monday.
Absolute Software’s Growth Trajectory Unlikely To Be Affected By CRO Departure, Analyst Says
Needham analyst Scott Berg reiterated a Buy on Absolute Software Corp (NASDAQ:ABST) and a $14 price target. In what is quickly becoming…
